“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Cantargia
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
• Please explain the link between cancer, autoimmune and inflammatory disorders.
• How does CAN04 differ from other treatments?
• What results have you seen in recent CAN04 tests?
• What is your R&D strategy for nadunolimab?
• What data should we expect and when?
• How does your other asset, CAN10, which has an autoimmune focus, fit in your plans?
Get access to the very latest content matched to your personal investment style.
